Mutations of the BRAF gene in human cancer, Nature, vol.417, pp.949-954, 2002. ,
Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N. Engl. J. Med, vol.364, pp.2507-2516, 2011. ,
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling, J. Clin. Oncol, vol.29, pp.3085-3096, 2011. ,
Secondary tumors arising in patients undergoing BRAF inhibitor therapy exhibit increased BRAF-CRAF heterodimerization, Cancer Res, vol.76, pp.1476-1485, 2016. ,
Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers, Oncotarget, vol.2, pp.336-346, 2011. ,
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition, Nature, vol.504, pp.138-142, 2013. ,
Overcoming resistance to BRAF inhibitors, Ann. Transl. Med, vol.5, p.387, 2017. ,
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma, Nat. Commun, vol.5, p.5712, 2014. ,
Cancer drug addiction is relayed by an ERK2-dependent phenotype switch, Nature, vol.550, pp.270-274, 2017. ,
Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress, Cancer Cell, vol.33, pp.890-904, 2018. ,
Toward minimal residual disease-directed therapy in melanoma, Cell, vol.174, pp.843-855, 2018. ,
MAPK pathway inhibitors sensitize BRAF mutant melanoma to an antibody-drug conjugate targeting GPNMB, Clin. Cancer Res, vol.949, pp.6088-6098, 2016. ,
Non-genomic and immune evolution of melanoma acquiring MAPKi resistance, Cell, vol.162, pp.1271-1285, 2015. ,
Cancer stem cells versus phenotype-switching in melanoma, Pigment Cell Melanoma Res, vol.23, pp.746-759, 2010. ,
Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state, Nat. Commun, vol.6, p.6683, 2015. ,
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance, Nature, vol.546, p.431, 2017. ,
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex, Nature, vol.517, pp.61422-61427, 2015. ,
Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals, Annu. Rev. Pharmacol. Toxicol, vol.43, pp.309-334, 2003. ,
Aryl hydrocarbon receptor activation by dioxin targets phosphoenolpyruvate carboxykinase (PEPCK) for ADP-ribosylation via 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-inducible poly(ADP-ribose) polymerase (TiPARP), J. Biol. Chem, vol.288, pp.21514-21525, 2013. ,
Aryl-hydrocarbon receptor-deficient mice are resistant to 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced toxicity, Toxicol. Appl. Pharmacol, vol.140, pp.173-179, 1996. ,
The aryl hydrocarbon receptor: fine-tuning the immune-response, Curr. Opin. Immunol, vol.22, pp.747-752, 2010. ,
Ligand binding and activation of the Ah receptor, Chem. Biol. Interact, vol.141, pp.3-24, 2002. ,
Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target, Toxicol. Sci, vol.135, pp.1-16, 2013. ,
RAF inhibitors that evade paradoxical MAPK pathway activation, Nature, vol.526, pp.583-586, 2015. ,
MAPK pathway inhibitors sensitize BRAF-mutant melanoma to an antibody-drug conjugate targeting GPNMB, Clin. Cancer Res, vol.22, pp.6088-6098, 2016. ,
Inhibiting drivers of non-mutational drug tolerance is a salvage strategy for targeted melanoma therapy, Cancer Cell, vol.29, pp.270-284, 2016. ,
The etiology of oculocutaneous albinism (OCA) type II: the pink protein modulates the processing and transport of tyrosinase, Pigment Cell Res, vol.15, pp.217-224, 2002. ,
BRAFi and AhR antagonists (Resveratrol and CH-223191). b Binding model of the antagonist Resveratrol (RSV) to the PAS B of AHR. RSV is predicted to bind to the ?-pocket. Free binding energy is reported in Supplementary Table 1. c RSV prevents CYP1A1 mRNA induction (48 h) by TCDD. 501Mel cells were pre-treated with 5 ?M RSV 2 h before 10 nM TCDD. d Gene expression profile of 501Mel cells exposed to vehicle, Therapeutic opportunity to limit BRAFi resistance. a Heatmap depicting the effects of different AhR ligands on OCA2 and CYP1A1 mRNA in 501Mel cells and pigmentation (48 h). Three groups: exo-and endo-gene ligands ,
, every 2 days) before treatment with Vem in order to establish Vem IC50 3 days after BRAFi treatment. Values, calculated with GraphPad PRISM (i), represent IC50 of Vem for control cells (without RSV pre-treatment) or after 1 week of RSV (j). % of BRAFi-persister cell values correspond to the percentage of residual cells following 3 days of Vem (5 ?M) treatment in comparison to melanoma cells without RSV treatment (k). l PDX tumor volumes 14 days after daily treatment with Dabrafenib (30 mg/kg) (n = 8) or in combination with RSV (40 mg/kg) (n = 7). m Number of days to reach max tumor volume (endpoint: >800 mm 3 ). Values correspond to the mean ± sem, Two pairs of BRAFi-sensitive (S) and -resistant (R) melanoma cells (501Mel and SKMel28) were pre-treated or not for 1 week with RSV (1 ?M
Unrevealing the role of P-protein on melanosome biology and structure, using siRNA-mediated down regulation of OCA2, Mol. Cell Biochem, vol.403, pp.61-71, 2015. ,
The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity, Nature, vol.483, pp.603-607, 2012. ,
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex, Nature, vol.517, pp.583-588, 2015. ,
BRAF(V600E) kinase domain duplication identified in therapy-refractory melanoma patient-derived xenografts, Cell Rep, vol.16, pp.263-277, 2016. ,
Recurrent tumor cell-intrinsic and -extrinsic alterations during MAPKi-induced melanoma regression and early adaptation, Cancer Discov, vol.7, pp.1248-1265, 2017. ,
Dissecting the multicelllular ecosystem of metastatic melanoma by single-cell RNA-seq, Science, vol.352, pp.189-196, 2016. ,
Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity, Mol. Pharmacol, vol.56, pp.784-790, 1999. ,
Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells, Carcinogenesis, vol.25, pp.2005-2013, 2004. ,
A non-coding function of TYRP1 mRNA promotes melanoma growth, Nat. Cell Biol, vol.19, p.1348, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01647130
Role for the aryl hydrocarbon receptor and diverse ligands in oral squamous cell carcinoma migration and tumorigenesis, Mol. Cancer Res, vol.14, pp.696-706, 2016. ,
Malignant transformation of mammary epithelial cells by ectopic overexpression of the aryl hydrocarbon receptor, Curr. Cancer Drug. Targets, vol.11, pp.654-669, 2011. ,
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor, Nature, vol.478, pp.197-203, 2011. ,
Prognostic value of nuclear translocation of aryl hydrocarbon receptor for non-small cell lung cancer, Anticancer Res, vol.33, pp.3953-3961, 2013. ,
The aryl hydrocarbon receptor in the crossroad of signalling networks with therapeutic value, Pharmacol. Ther, vol.185, pp.50-63, 2018. ,
Towards resolving the pro-and anti-tumor effects of the aryl hydrocarbon receptor, Int. J. Mol. Sci, vol.19, p.1388, 2018. ,
The aryl hydrocarbon receptor mediates leflunomideinduced growth inhibition of melanoma cells, PLoS One, vol.7, p.40926, 2012. ,
The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth, Oncotarget, vol.9, pp.3815-3829, 2018. ,
Dioxin receptor regulates aldehyde dehydrogenase to block melanoma tumorigenesis and metastasis, Mol. Cancer, vol.14, p.148, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-01264498
New trends in aryl hydrocarbon receptor biology, Front. Cell Dev. Biol, vol.4, pp.1-14, 2016. ,
Genetic alterations driving metastatic colony formation are acquired outside of the primary tumour in melanoma, Nat. Commun, vol.9, p.595, 2018. ,
STAT3/p53 pathway activation disrupts IFN-?-induced dormancy in tumor-repopulating cells, J. Clin. Invest, vol.128, pp.1057-1073, 2018. ,
The aryl hydrocarbon receptor mediates UVB radiation-induced skin tanning, J. Invest. Dermatol, vol.131, pp.203-210, 2011. ,
A. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces matrix metalloproteinase (MMP) expression and invasion in A2058 melanoma cells, Toxicol. Appl. Pharmacol, vol.210, pp.212-224, 2006. ,
URL : https://hal.archives-ouvertes.fr/hal-01311566
Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target, Arch. Toxicol, vol.91, pp.2497-2513, 2017. ,
Regulation of the immune response by the aryl hydrocarbon receptor, Immunity, vol.48, pp.19-33, 2018. ,
Activation of the aryl hydrocarbon receptor by the calcium/calmodulin-dependent protein kinase kinase inhibitor 7-oxo-7H-benzimidazo, Drug Metab. Dispos, vol.36, pp.2556-2563, 2008. ,
URL : https://hal.archives-ouvertes.fr/hal-00673111
An analysis of Mek1 signaling in cell proliferation and transformation, J. Biol. Chem, vol.273, pp.13280-13288, 1998. ,
AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility, J. Comput. Chem, vol.30, pp.2785-2791, 2009. ,
Structural and functional characterization of the aryl hydrocarbon receptor ligand binding domain by homology modeling and mutational analysis, Biochemistry, vol.46, pp.696-708, 2007. ,
RNAi-based screening identifies kinases interfering with dioxinmediated up-regulation of CYP1A1 activity, PLoS One, vol.6, p.18261, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00586840
A novel prenylflavone restricts breast cancer cell growth through AhR-mediated destabilization of ER? protein, Carcinogenesis, vol.33, pp.1089-1097, 2012. ,
Ligand promiscuity of aryl hydrocarbon receptor agonists and antagonists revealed by site-directed mutagenesis, Mol. Cell Biol, vol.34, pp.1707-1719, 2014. ,
p53 requires the stress sensor USF1 to direct appropriate cell fate decision, PLoS Genet, vol.10, p.1004309, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01064584
Cyclical DNA methylation of a transcriptionally active promoter, Nature, vol.452, p.45, 2008. ,
OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs, PeerJ Comput. Sci, vol.2, p.67, 2016. ,
Comparative analysis of TCDD-induced AhR-mediated gene expression in human, mouse and rat primary B cells, Toxicol. Appl. Pharmacol, vol.316, pp.95-106, 2017. ,